Ixazomib (MLN-2238)
Ixazomib (MLN2238) (commercial name: Ninlaro®) is the first and only FDA-approved oral proteasome inhibitor for the treatment of multiple myeloma. It reversibly inhibits the chymotrypsin-like activity of proteasomes with IC50 of 3.4 nM in cell-free assays, also inhibits the caspase-like and trypsin-like activities of proteasome with IC50 of 31 and 3500 nM, respectively.
Product Name:
Ixazomib (MLN-2238)
>Also Known As:
[(1R)-1-[[(2S,3R)-3-hydroxy-2-[(6-phenylpyridine-2-carbonyl)amino]butanoyl]amino]-3-methylbutyl]boronic acid
>Catalog No.:
F1110
>Size:
5 mg
>CAS:
1072833-77-2
>Formula:
C14H19BCl2N2O4
>Molecular Weight:
361.03 Da
>Form:
Lyophilized powder
>Quality Assurance:
>98% by HPLC and NMR
>Source:
Synthetic
>Storage:
Eligible for room temperature shipping. Store at -80°C upon receiving
>PDF Data Sheet:
Download PDF datasheet
>Image(s):
N/A
>Shipping Method:
Room temperature shipping
>References:
N/A CPI-203 18479426
